S&P 500   3,932.61 (-0.22%)
DOW   33,594.57 (+-0.01%)
QQQ   280.03 (-0.59%)
AAPL   141.05 (-1.30%)
MSFT   244.28 (-0.34%)
META   113.59 (-0.46%)
GOOGL   95.49 (-1.54%)
AMZN   88.07 (-0.20%)
TSLA   172.26 (-4.20%)
NVDA   159.61 (-0.16%)
NIO   12.47 (-5.82%)
BABA   88.46 (-3.27%)
AMD   70.65 (+0.54%)
T   19.34 (+0.89%)
MU   53.56 (-0.22%)
CGC   3.36 (-6.93%)
F   13.29 (+0.08%)
GE   85.20 (-0.09%)
DIS   92.24 (-0.05%)
AMC   6.51 (-3.56%)
PYPL   74.32 (+2.89%)
PFE   50.44 (+1.47%)
NFLX   305.84 (+0.09%)
S&P 500   3,932.61 (-0.22%)
DOW   33,594.57 (+-0.01%)
QQQ   280.03 (-0.59%)
AAPL   141.05 (-1.30%)
MSFT   244.28 (-0.34%)
META   113.59 (-0.46%)
GOOGL   95.49 (-1.54%)
AMZN   88.07 (-0.20%)
TSLA   172.26 (-4.20%)
NVDA   159.61 (-0.16%)
NIO   12.47 (-5.82%)
BABA   88.46 (-3.27%)
AMD   70.65 (+0.54%)
T   19.34 (+0.89%)
MU   53.56 (-0.22%)
CGC   3.36 (-6.93%)
F   13.29 (+0.08%)
GE   85.20 (-0.09%)
DIS   92.24 (-0.05%)
AMC   6.51 (-3.56%)
PYPL   74.32 (+2.89%)
PFE   50.44 (+1.47%)
NFLX   305.84 (+0.09%)
S&P 500   3,932.61 (-0.22%)
DOW   33,594.57 (+-0.01%)
QQQ   280.03 (-0.59%)
AAPL   141.05 (-1.30%)
MSFT   244.28 (-0.34%)
META   113.59 (-0.46%)
GOOGL   95.49 (-1.54%)
AMZN   88.07 (-0.20%)
TSLA   172.26 (-4.20%)
NVDA   159.61 (-0.16%)
NIO   12.47 (-5.82%)
BABA   88.46 (-3.27%)
AMD   70.65 (+0.54%)
T   19.34 (+0.89%)
MU   53.56 (-0.22%)
CGC   3.36 (-6.93%)
F   13.29 (+0.08%)
GE   85.20 (-0.09%)
DIS   92.24 (-0.05%)
AMC   6.51 (-3.56%)
PYPL   74.32 (+2.89%)
PFE   50.44 (+1.47%)
NFLX   305.84 (+0.09%)
S&P 500   3,932.61 (-0.22%)
DOW   33,594.57 (+-0.01%)
QQQ   280.03 (-0.59%)
AAPL   141.05 (-1.30%)
MSFT   244.28 (-0.34%)
META   113.59 (-0.46%)
GOOGL   95.49 (-1.54%)
AMZN   88.07 (-0.20%)
TSLA   172.26 (-4.20%)
NVDA   159.61 (-0.16%)
NIO   12.47 (-5.82%)
BABA   88.46 (-3.27%)
AMD   70.65 (+0.54%)
T   19.34 (+0.89%)
MU   53.56 (-0.22%)
CGC   3.36 (-6.93%)
F   13.29 (+0.08%)
GE   85.20 (-0.09%)
DIS   92.24 (-0.05%)
AMC   6.51 (-3.56%)
PYPL   74.32 (+2.89%)
PFE   50.44 (+1.47%)
NFLX   305.84 (+0.09%)

Nevro - NVRO Stock Forecast, Price & News

$41.96
+0.31 (+0.74%)
(As of 12/7/2022 11:56 AM ET)
Add
Compare
Today's Range
$41.32
$42.40
50-Day Range
$36.43
$49.40
52-Week Range
$34.70
$98.12
Volume
11,869 shs
Average Volume
369,176 shs
Market Capitalization
$1.49 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$64.50

Nevro MarketRank™ Forecast

Analyst Rating
Hold
2.07 Rating Score
Upside/​Downside
54.9% Upside
$64.50 Price Target
Short Interest
Bearish
9.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.69) to ($2.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

594th out of 1,023 stocks

Surgical & Medical Instruments Industry

63rd out of 102 stocks

NVRO stock logo

About Nevro (NYSE:NVRO) Stock

Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It also provides 10 kHz Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was incorporated in 2006 and is headquartered in Redwood City, California.

Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

NVRO Stock News Headlines

Analysts Set Nevro Corp. (NYSE:NVRO) Target Price at $64.50
4 MedTech Stocks Set to Outpace Q3 Earnings Estimates
What 4 Analyst Ratings Have To Say About Nevro
Why Is Nevro (NVRO) Down 1% Since Last Earnings Report?
Nevro's (NVRO) PDN Therapy Gets Positive Coverage Updates
See More Headlines
Receive NVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter.

NVRO Company Calendar

Last Earnings
11/02/2022
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
945
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$64.50
High Stock Price Forecast
$97.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+53.7%
Consensus Rating
Hold
Rating Score (0-4)
2.07
Research Coverage
14 Analysts

Profitability

Net Income
$-131,360,000.00
Pretax Margin
-1.80%

Debt

Sales & Book Value

Annual Sales
$386.90 million
Book Value
$8.70 per share

Miscellaneous

Free Float
34,438,000
Market Cap
$1.49 billion
Optionable
Optionable
Beta
0.82

Key Executives

  • Mr. D. Keith GrossmanMr. D. Keith Grossman (Age 62)
    Chairman, CEO & Pres
    Comp: $857.84k
  • Mr. Roderick H. MacLeod (Age 55)
    Chief Financial Officer
    Comp: $458.2k
  • Mr. Kashif RashidMr. Kashif Rashid (Age 48)
    Gen. Counsel, Corp. Sec. & Chief Compliance Officer
    Comp: $437.6k
  • Ms. Niamh Louise Pellegrini (Age 55)
    Chief Commercial Officer
    Comp: $482.4k
  • Mr. Patrick Schmitz (Age 62)
    VP of Operations
  • Mr. Richard B. Carter (Age 51)
    Chief Accounting Officer
  • Ms. Julie D. Dewey (Age 61)
    Chief Corp. Communications & Investor Relations Officer
  • Mr. Michael Collier Carter (Age 50)
    VP of Global Sales
  • Mr. Jon R. Shear
    VP of Corp. Devel.
  • Meredith Vornholt
    VP of Global Marketing













NVRO Stock - Frequently Asked Questions

Should I buy or sell Nevro stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 3 sell ratings, 7 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View NVRO analyst ratings
or view top-rated stocks.

What is Nevro's stock price forecast for 2023?

14 brokerages have issued 1-year price targets for Nevro's shares. Their NVRO share price forecasts range from $31.00 to $97.00. On average, they predict the company's share price to reach $64.50 in the next twelve months. This suggests a possible upside of 53.7% from the stock's current price.
View analysts price targets for NVRO
or view top-rated stocks among Wall Street analysts.

How have NVRO shares performed in 2022?

Nevro's stock was trading at $81.07 at the beginning of 2022. Since then, NVRO stock has decreased by 48.2% and is now trading at $41.96.
View the best growth stocks for 2022 here
.

Are investors shorting Nevro?

Nevro saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 3,330,000 shares, an increase of 58.6% from the October 15th total of 2,100,000 shares. Based on an average daily volume of 629,700 shares, the short-interest ratio is presently 5.3 days. Currently, 10.0% of the company's stock are short sold.
View Nevro's Short Interest
.

When is Nevro's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our NVRO earnings forecast
.

How were Nevro's earnings last quarter?

Nevro Corp. (NYSE:NVRO) announced its quarterly earnings data on Wednesday, November, 2nd. The medical equipment provider reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $0.09. The medical equipment provider had revenue of $100.47 million for the quarter, compared to analysts' expectations of $99.08 million. Nevro had a negative trailing twelve-month return on equity of 40.89% and a negative net margin of 2.01%.

What guidance has Nevro issued on next quarter's earnings?

Nevro issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $403.00 million-$407.00 million, compared to the consensus revenue estimate of $405.06 million.

What is D. Keith Grossman's approval rating as Nevro's CEO?

9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Nevro own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

What is Nevro's stock symbol?

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Who are Nevro's major shareholders?

Nevro's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.75%), Vanguard Group Inc. (10.22%), Fred Alger Management LLC (2.63%), Federated Hermes Inc. (2.35%), State Street Corp (2.32%) and Brown Advisory Inc. (1.82%). Insiders that own company stock include Andrew H Galligan, D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends
.

How do I buy shares of Nevro?

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nevro's stock price today?

One share of NVRO stock can currently be purchased for approximately $41.96.

How much money does Nevro make?

Nevro (NYSE:NVRO) has a market capitalization of $1.49 billion and generates $386.90 million in revenue each year. The medical equipment provider earns $-131,360,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis.

How many employees does Nevro have?

The company employs 945 workers across the globe.

How can I contact Nevro?

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The official website for the company is www.nevro.com. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at ir@nevro.com.

This page (NYSE:NVRO) was last updated on 12/7/2022 by MarketBeat.com Staff